Jermaine I. Coward

Raymond Terrace
South Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer.

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer.

Journal: British journal of cancer

Published: July 24, 2025

Immunometabolism: The role of gut-derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy.

Immunometabolism: The role of gut-derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy.

Journal: Clinical and translational medicine

Published: May 22, 2025

High-throughput surface epitope immunoaffinity isolation of extracellular vesicles and downstream analysis.

High-throughput surface epitope immunoaffinity isolation of extracellular vesicles and downstream analysis.

Journal: Biology methods & protocols

Published: April 03, 2024

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context.

Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context.

Journal: The Australian & New Zealand journal of obstetrics & gynaecology

Published: February 20, 2023

Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.

Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.

Journal: Cancers

Published: May 31, 2021

Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy.

Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: September 10, 2020

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.

Journal: Cancers

Published: March 10, 2020

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.

Journal: British journal of cancer

Published: November 10, 2015

New perspectives on targeted therapy in ovarian cancer.

New perspectives on targeted therapy in ovarian cancer.

Journal: International journal of women's health

Published: February 14, 2015

The tolerability of sunitinib in elderly patients with metastatic renal cancer.

The tolerability of sunitinib in elderly patients with metastatic renal cancer.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: January 05, 2015

Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

Journal: Oncogene

Published: September 22, 2014

EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.

EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.

Journal: Oncogene

Published: November 24, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026